Background The clinical armamentarium for anticoagulation has expanded substantially
since the recent approval of dabigatran, rivaroxaban and apixaban for the prevention of …

Purpose Since 2011, several direct oral anticoagulants (DOACs; dabigatran, rivaroxaban,
apixaban) have been introduced as alternatives to warfarin for stroke prophylaxis in atrial …

Background Dabigatran, rivaroxaban, and apixaban have been approved for use in patients
with atrial fibrillation based upon randomized trials demonstrating their comparable or …

Objective: Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke in
patients with atrial fibrillation (AF). The study characterized the prescribing of OACs in …

Background—Little is known regarding the adoption of direct thrombin inhibitors in clinical
practice. We examine trends in oral anticoagulation for the prevention of thromboembolism …

The study objective was to evaluate the safety and effectiveness of dabigatran and other
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …

Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …

BACKGROUND: As alternatives to warfarin, 2 novel oral anticoagulants (NOACs),
dabigatran and rivaroxaban, were approved in 2010 and 2011 to prevent stroke and other …

Atrial fibrillation (AF) is a common cardiovascular disease for which newer oral
anticoagulants are available. The main objective of this study was to evaluate the …

Background Dabigatran is one of the three newer oral anticoagulants (OACs) recently
approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) …